DRREDDY.BO : Summary for DR.REDDYS LABORATORIES LTD. - Yahoo Finance

U.S. Markets close in 3 hrs 30 mins

Dr. Reddy's Laboratories Ltd. (DRREDDY.BO)


BSE - BSE Delayed Price. Currency in INR
Add to watchlist
2,890.15-9.10 (-0.31%)
At close: 3:40PM IST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2,899.25
Open2,920.00
Bid0.00 x
Ask0.00 x
Day's Range2,881.10 - 2,920.00
52 Week Range2,803.50 - 3,689.00
Volume14,275
Avg. Volume30,483
Market Cap493.08B
BetaN/A
PE Ratio (TTM)24.71
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Dr. Reddy’s Laboratories Ltd. :500124-IN: Earnings Analysis: Q3, 2017 By the Numbers : February 9, 2017
    Capital Cube15 days ago

    Dr. Reddy’s Laboratories Ltd. :500124-IN: Earnings Analysis: Q3, 2017 By the Numbers : February 9, 2017

    Categories: Yahoo Finance Get free summary analysis Dr. Reddy’s Laboratories Ltd. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Dr. Reddy’s Laboratories Ltd. – Wockhardt Limited, Novartis India Limited, Glenmark Pharmaceuticals Limited and Cadila Healthcare Limited (532300-IN, 500672-IN, 532296-IN and 532321-IN) that have also reported for ... Read more (Read more...)

  • Dr. Reddy’s Laboratories Ltd. breached its 50 day moving average in a Bearish Manner : 500124-IN : February 9, 2017
    Capital Cube15 days ago

    Dr. Reddy’s Laboratories Ltd. breached its 50 day moving average in a Bearish Manner : 500124-IN : February 9, 2017

    Categories: Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Dr. Reddy’s Laboratories Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day ... Read more (Read more...)

  • American City Business Journals17 days ago

    BioMarin sues to stop generic version of its $90K-a-year drug

    Rare-disease drug developer BioMarin Pharmaceutical Inc. sued an Indian drug maker that plans to make and sell a version of one of BioMarin's top-selling drugs. The San Rafael company (BMRN), led by CEO Jean-Jacques Bienaimé, said in a filing Monday in U.S. District Court in New Jersey that a version of the drug Kuvan by Dr. Reddy's Laboratories Ltd. infringes on six BioMarin patents. The Indian company late last year asked the Food and Drug Administration to approve its powder version of Kuvan, saying that BioMarin's patents are invalid, unenforceable or will not be infringed by manufacturing, use or sale.